Stock Price

Specialist asset manager Sprott Inc. leverages a volatile market and geopolitical tensions, riding a precious metals boom to record profits and AUM growth.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

Creative Realities repurchased 1.7M stock warrants for just $200,000, a strategic move to prevent dilution and pave the way for ambitious growth.

As it marks 40 years, Heidmar (NASDAQ: HMR) appoints 40-year industry expert Jagmeet Makkar to its board to navigate a turbulent tanker market.

Polestar unveils a bold plan to launch four new models by 2028, but can the EV maker overcome financial hurdles and intense market competition?

Getty Realty Corp. raises $131 million in a strategic stock offering, using a sophisticated forward sale to fund acquisitions and bolster its balance sheet.

With a $50.1M financing led by top investors, Coherus solidifies its strategic pivot from biosimilars to a pure-play oncology powerhouse.

As Adagene presents at key conferences, its SAFEbody tech and lead drug muzastotug draw focus amid a strategic push for funding and partnerships.

Ditching passive holding, Lite Strategy generated $600k from Litecoin options to fund buybacks. Is this the new playbook for corporate crypto finance?

An OTC-listed company's $11.7M deal for a Texas power plant highlights a critical trend: the race to secure private energy for the AI revolution.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

A strategic merger creates a new aerospace and defense giant, but existing shareholders face significant dilution in a deal laden with both promise and risk.

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

After a soft 2025, Graphic Packaging's CEO faces investors. With the stock lagging, all eyes are on whether its green strategy can deliver growth.

Acurx Pharmaceuticals preps for pivotal Phase 3 trials for its novel C. diff antibiotic, Ibezapolstat, with global regulatory alignment in place.

Hong Kong's Powell Max resolved a critical Nasdaq compliance issue, but a look at its finances and a second regulatory notice reveals greater challenges.

Lay's emotional 'Last Harvest' was America's top Super Bowl ad, but a new report reveals a huge generational divide, with Gen Z crowning a different winner.

Nektar Therapeutics secures a massive $400M offering, signaling strong investor faith in its lead drug, rezpegaldesleukin, for autoimmune diseases.

At a key summit, Candel Therapeutics will showcase how its oncolytic virus, CAN-3110, uses biomarkers to fight one of the deadliest brain cancers.

Investors await Alkane's H1 results for insights on its post-merger performance, Boda-Kaiser project, and standing in a surging commodities market.